AAAAAA

   
Results: 1-8 |
Results: 8
Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens
Authors: Nordoy, T Kolstad, A Tuck, MK Aaberge, IS Husebekk, A Kaminski, MS
Citation: T. Nordoy et al., Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens, CLIN IMMUNO, 100(1), 2001, pp. 40-48
Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
Authors: Kaminski, MS Zelenetz, AD Press, OW Saleh, M Leonard, J Fehrenbacher, L Lister, TA Stagg, RJ Tidmarsh, GF Kroll, S Wahl, RL Knox, SJ Vose, JM
Citation: Ms. Kaminski et al., Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, J CL ONCOL, 19(19), 2001, pp. 3918-3928
Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report
Authors: Koral, KF Dewaraja, Y Clarke, LA Li, J Zasadny, KR Rommelfanger, SG Francis, IR Kaminski, MS Wahl, RL
Citation: Kf. Koral et al., Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report, CANC BIO R, 15(4), 2000, pp. 347-355
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
Authors: Vose, JM Wahl, RL Saleh, M Rohatiner, AZ Knox, SJ Radford, JA Zelenetz, AD Tidmarsh, GF Stagg, RJ Kaminski, MS
Citation: Jm. Vose et al., Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas, J CL ONCOL, 18(6), 2000, pp. 1316-1323
Initial results for hybrid SPECT-conjugate-view tumor dosimetry in I-131-anti-B-1 antibody therapy of previously untreated patients with lymphoma
Authors: Koral, KF Dewaraja, Y Li, J Barrett, CL Regan, DD Zasadny, KR Rommelfanger, SG Francis, IR Kaminski, MS Wahl, RL
Citation: Kf. Koral et al., Initial results for hybrid SPECT-conjugate-view tumor dosimetry in I-131-anti-B-1 antibody therapy of previously untreated patients with lymphoma, J NUCL MED, 41(9), 2000, pp. 1579-1586
Metabolic response of non-Hodgkin's lymphoma to I-131-anti-B1 radioimmunotherapy: Evaluation with FDG PET
Authors: Torizuka, T Zasadny, KR Kison, PV Rommelfanger, SG Kaminski, MS Wahl, RL
Citation: T. Torizuka et al., Metabolic response of non-Hodgkin's lymphoma to I-131-anti-B1 radioimmunotherapy: Evaluation with FDG PET, J NUCL MED, 41(6), 2000, pp. 999-1005
Radioimmunotherapy with iodine I-131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
Authors: Kaminski, MS Estes, J Zasadny, KR Francis, IR Ross, CW Tuck, M Regan, D Fisher, S Gutierrez, J Kroll, S Stagg, R Tidmarsh, G Wahl, RL
Citation: Ms. Kaminski et al., Radioimmunotherapy with iodine I-131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience, BLOOD, 96(4), 2000, pp. 1259-1266
I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusionof tracer images to computed tomography images
Authors: Koral, KF Li, J Dewaraja, Y Barrett, CL Regan, DD Zasadny, KR Rommelfanger, SG Francis, IR Kaminski, MS Wahl, RL
Citation: Kf. Koral et al., I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusionof tracer images to computed tomography images, CLIN CANC R, 5(10), 1999, pp. 3004S-3009S
Risultati: 1-8 |